Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest diabetic gastroparesis Stories

2013-05-20 08:27:43

BOSTON, May 20, 2013 /PRNewswire/ -- Rhythm announced today the results of a second Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis in type 1 diabetic patients. The trial demonstrated that RM-131 significantly accelerates early gastric emptying and reduces upper gastrointestinal (GI) symptoms in type 1 diabetic patients with diabetic gastroparesis. The findings were presented at the Digestive Disease Week 2013 conference in...

2013-05-20 08:27:40

-- Despite high prevalence of symptoms, rate of gastroparesis diagnosis is low among those with type 2 diabetes -- BOSTON, May 20, 2013 /PRNewswire/ -- Rhythm announced today the presentation of results from a new epidemiology study demonstrating a higher prevalence of gastroparesis symptoms among diabetic patients in the U.S. than previously recognized. Prevalence of these symptoms is high among patients with both type 1 and type 2 diabetes, but this condition is significantly...

2013-04-16 08:28:12

BOSTON, April 16, 2013 /PRNewswire/ -- Rhythm announced today the initiation of an additional Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of chronic constipation. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal motility. "This is the first of two studies we plan to initiate this year to assess the efficacy and safety of RM-131 for the treatment of lower GI functional disorders," said Elizabeth Stoner, MD,...

2012-06-06 06:26:33

BOSTON, June 6, 2012 /PRNewswire/ -- Rhythm announced today the initiation of a Phase 2 clinical trial for RM-131, the company's novel ghrelin agonist, for the treatment of gastroparesis in patients with Type I and Type II diabetes. Ghrelin is a peptide hormone produced in the stomach that stimulates gastric motility. "We are excited about the clinical profile of RM-131 as we bring it forward into Phase 2 development," said Liz Stoner, MD, Chief Development Officer of Rhythm. "Extensive...

2012-05-22 06:25:26

BOSTON, May 22, 2012 /PRNewswire/ -- Rhythm announced today the results of a Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis. The trial demonstrated that RM-131 greatly accelerates gastric emptying in patients with diabetic gastroparesis. The findings were presented at the Digestive Disease Week 2012 conference in San Diego. The Phase 1b clinical trial was a randomized, double-blind, placebo-controlled, single-dose crossover...

2009-05-05 08:05:00

SAN DIEGO, May 5 /PRNewswire/ -- - Evoke Pharma, Inc., a privately-held specialty pharmaceutical company, announced today that it has initiated a Phase 2b clinical trial to evaluate EVK-001 for the treatment of adults with symptoms of diabetic gastroparesis. Gastroparesis is a syndrome characterized by delayed emptying of the stomach into the intestine following a meal in the absence of mechanical obstruction. Diabetes is an important cause of gastroparesis, but other identified causes...